Anavex Life Sciences Advances Alzheimer’s Research with Promising Results
Anavex Life Sciences has made significant strides in Alzheimer’s disease research with its investigational oral therapy, Anavex 2-73, also known as blarcamesine. Recent data from a Phase 2b/3 clinical trial highlights the drug’s capability to decelerate cognitive and functional decline in patients with early-stage Alzheimer’s. This development is particularly noteworthy given the complex challenges posed…